Your browser is no longer supported. Please, upgrade your browser.
OSIR Osiris Therapeutics, Inc. daily Stock Chart
Osiris Therapeutics, Inc.
Index- P/E52.37 EPS (ttm)0.30 Insider Own52.10% Shs Outstand33.01M Perf Week4.05%
Market Cap525.52M Forward P/E- EPS next Y- Insider Trans- Shs Float12.43M Perf Month9.12%
Income10.50M PEG- EPS next Q- Inst Own26.20% Short Float1.87% Perf Quarter48.79%
Sales134.60M P/S3.90 EPS this Y195.00% Inst Trans13.71% Short Ratio2.16 Perf Half Y100.25%
Book/sh1.33 P/B11.97 EPS next Y- ROA7.80% Target Price4.00 Perf Year92.97%
Cash/sh1.22 P/C13.01 EPS next 5Y- ROE15.00% 52W Range7.01 - 15.85 Perf YTD17.93%
Dividend- P/FCF59.05 EPS past 5Y21.00% ROI10.20% 52W High0.44% Beta0.79
Dividend %- Quick Ratio1.90 Sales past 5Y72.10% Gross Margin72.10% 52W Low127.10% ATR0.65
Employees337 Current Ratio2.20 Sales Q/Q22.50% Oper. Margin2.50% RSI (14)69.55 Volatility3.04% 4.32%
OptionableYes Debt/Eq0.00 EPS Q/Q286.60% Profit Margin4.70% Rel Volume1.72 Prev Close15.22
ShortableYes LT Debt/Eq0.00 EarningsFeb 27 Payout0.00% Avg Volume107.98K Price15.92
Recom- SMA206.90% SMA5015.68% SMA20048.42% Volume180,693 Change4.60%
Jan-24-19 05:38PM  Hagens Berman: Notice to Osiris Therapeutics, Inc. Investors: Less than One Week Left to File Claims to Receive Part of $18.5 Million Settlement Business Wire
Jan-15-19 07:21PM  Hagens Berman Notifies Osiris Therapeutics, Inc. Investors of Class Action Settlement and January 30, 2019 Claims Deadline Business Wire
Dec-05-18 02:10PM  Is Abraxas Petroleum Corp. (NASDAQ:AXAS) A Good Stock To Buy? Insider Monkey
Nov-26-18 04:30PM  Osiris Therapeutics, Inc. Appoints Samson Tom, PhD, MBA to Serve as President and Chief Executive Officer GlobeNewswire
Nov-19-18 08:20AM  Report: Exploring Fundamental Drivers Behind iPic Entertainment, Smith Micro Software, Northern Technologies International, Intevac, Helius Medical Technologies, and Osiris Therapeutics New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Nov-07-18 07:43PM  Osiris: 3Q Earnings Snapshot Associated Press
04:15PM  Osiris Therapeutics, Inc Reports Third Quarter 2018 Results GlobeNewswire
Oct-30-18 04:30PM  Osiris Therapeutics, Inc. to Present Advanced Clinical and Scientific Abstracts at Symposium on Advanced Wound Care (SAWC) Fall Meeting, November 2-4, 2018, in Las Vegas, Nevada GlobeNewswire
Oct-02-18 04:30PM  Osiris Therapeutics, Inc. Announces Peer-Reviewed Publication Demonstrating That Lyopreservation Method Developed for Living Tissues is an Alternative to Cryopreservation with the Convenience of Ambient Storage GlobeNewswire
Sep-18-18 08:44AM  The Daily Biotech Pulse: Morphosys Expands Collaboration, Osiris Announces Product Launch, Argenx To Offer Shares Benzinga
Sep-17-18 05:00PM  Osiris Therapeutics, Inc. Announces GrafixPL PRIME Launches October 1, 2018 GlobeNewswire
Aug-28-18 08:13AM  The Daily Biotech Pulse: Regulatory Roadblock For Akcea-Ionis, Affimed's Alliance, FDA Nod For Tetraphase's Antibiotic Benzinga
Aug-27-18 04:30PM  Osiris Therapeutics, Inc. Announces Peer-Reviewed Publication Comparing the Efficacy of Viable Cryopreserved Placental Membranes to Human Fibroblast-Derived Dermal Substitute in the Treatment of Chronic Diabetic Foot Ulcers (DFUs) in a Multicenter Randomized Clinical Trial GlobeNewswire
Aug-01-18 08:00AM  Osiris Therapeutics, Inc. to Re-list on The Nasdaq Global Market on August 1, 2018 GlobeNewswire
Jul-11-18 04:30PM  Osiris Announces Enrollment of Patients in a Clinical Trial Evaluating GrafixPL PRIME in the Treatment of Chronic Venous Leg Ulcers GlobeNewswire
Jun-04-18 04:30PM  Osiris Announces Implementation of Prestige Lyotechnology Preservation Method Allowing Ambient Storage of Living Tissues GlobeNewswire
Nov-28-17 11:00AM  Update in Lawsuit for Investors in Osiris Therapeutics, Inc. (NASDAQ: OSIR) Shares Announced by Shareholders Foundation ACCESSWIRE
Nov-02-17 06:49PM  Former Osiris Therapeutics executive pleads guilty to false statements Reuters
Osiris Therapeutics, Inc. researches, develops, manufactures, markets, and distributes regenerative medicine products in the United States. Its products include Grafix and Stravix for treating chronic wounds of diabetic foot ulcers, venous leg ulcers, pressure ulcers, arterial ulcers, and severe burns, as well as surgical and trauma wounds; BIO4 for bone repair and regeneration in spine, trauma, extremity, cranial, and foot and ankle surgeries; and Cartiform for treating articular cartilage lesions in the knee and other joints. The company also develops and markets Menvivo for the repair of meniscus; and TruSkin for treating chronic wounds. It markets and distributes its products directly to physicians, hospitals, and other healthcare providers, as well as through agents and distributors. Osiris Therapeutics, Inc. was founded in 1992 and is headquartered in Columbia, Maryland.